logo-loader
STO:BIOPOR

BioPorto

Receive alerts
Market:
STO
Market Cap:
£0.00
Price
£0.00
Change
0%
52 weeks high
0
52 weeks low
0

Viewing results 1-13 of 13

Health

BioPorto sees boost in revenue in second quarter

The Danish in-vitro diagnostic company saw a boost in 2Q thanks to increased US revenues from its flagship NGAL Test and sales of antibodies...

4 days, 14 hours ago
Health

BioPorto completes private placing, raising around US$5.5M net

BioPorto’s gross proceeds from the raise amount to DKK 36,748,610, or US$ 5.6 million, the company said in a statement...

on 28/6/19
Health

Diagnostic company BioPorto taps Christopher Bird as chief medical officer

Christopher Bird joined the Denmark company from Roche Diagnostics Corp, a medical and scientific affairs organization...

on 26/6/19
Health

BioPorto private placement of more than 9.2 million shares fully subscribed

The aggregate subscription price for the new shares is DKK36,748,610, or US$5.5 million...

on 17/6/19
Health

BioPorto submits FDA application for approval of its proprietary kidney-injury test for use in children

The NGAL Test detects acute kidney injury, common after surgeries, faster and more reliably than standard tests...

on 15/5/19
Health

BioPorto's 1Q revenue increases 20% partly on sales of its flagship NGAL Test

The Danish in-vitro diagnostic company also got a boost by a slight increase in sales of antibodies...

on 9/5/19
Health

BioPorto places focus on flagship NGAL kidney-injury test

The Danish company is seeking FDA approval of the test for use in both adults and children...

on 6/5/19
Health

BioPorto names Amy Winslow president of US subsidiary as it prepares FDA applications

Before joining BioPorto, Winslow was president and CEO of Magellan Diagnostics in Boston...

on 15/4/19